Biotech funding beyond Series A: building a multi cycle capital strategy

Introduction

Biotech funding is rarely a one off event tied to a single Series A round. For CFOs, the real challenge is building a capital strategy that can carry assets through multiple clinical and regulatory cycles, using equity, partnerships and non dilutive tools in a deliberate sequence.

Why biotech funding is inherently multi cycle

Biotech businesses face a funding problem that is structurally different from most technology sectors. Development timelines are long, scientific risk is high and value inflection points are tied to clinical data and regulatory decisions.

A typical journey from preclinical work to Phase II or Phase III involves:

• Years of laboratory research and optimisation.
• Multiple rounds of animal and safety studies.
• Escalating costs as patient numbers rise and sites multiply.
• Regulatory interactions at national and international level.

It is unrealistic to expect a single Series A round to fund this trajectory. Instead, biotech funding must be planned as a sequence of raises and partnerships, each aligned to well defined milestones in the development pathway.

Mapping capital needs to the development pathway

A useful starting point for CFOs is to align capital planning with the scientific and clinical roadmap. Simplifying a complex reality, the journey can be broken into stages.

At each stage, the capital structure should reflect both the risk profile and the nature of the assets. For example, early preclinical work may be highly suited to grants and translational funding, while registration studies are more commonly supported by later stage equity and big pharma partnerships.

The building blocks of a multi cycle capital stack

Designing a resilient biotech capital stack means understanding the distinct roles of each instrument, then deciding when and how to deploy them.

Equity across multiple rounds

Equity is the backbone of most biotech funding strategies. It is typically required at:

• Seed and Series A, to fund discovery, preclinical work and initial clinical activity.
• Series B and beyond, to support proof of concept and pivotal trials.
• Potentially again at IPO or equivalent, to finance commercial build out.

For CFOs, the key questions are ownership and signalling. How much dilution can founders and early teams tolerate, and what does each round signal to regulators, partners and future investors about the quality of the data package and pipeline?

Venture debt and other credit facilities

Debt can have a role once there is sufficient visibility on future cash flows or partnership revenues. In biotech this may include:

• Venture debt facilities that extend runway between equity rounds.
• Royalty backed financings tied to specific products.
• Working capital lines connected to manufacturing or inventory.

However, leverage needs to be handled with care. Clinical setbacks or regulatory delays can stress covenants quickly, so downside scenarios must be modelled conservatively.

Strategic partnerships and licensing

Partnerships with big pharma or larger biotechs are both a scientific and a funding tool. They can provide:

• Upfront payments that reduce near term reliance on equity.
• Milestones and royalties that support long term investment.
• Access to clinical, regulatory and commercial infrastructure.

The trade off is value sharing and control. CFOs need to evaluate not only headline deal size, but also option structures, co development obligations and the impact on future fundraises.

Non dilutive tools: R&D tax relief and grant funding

Non dilutive sources are central to a multi cycle strategy:

• R&D tax relief can return a proportion of eligible scientific and clinical expenditure as cash or reduced tax, year after year.
• Grant funding from national and international bodies can support high risk projects, early translational work and collaborative studies with universities or health systems.

These tools cannot replace equity, but they can reduce the amount of equity required and help smooth cash demands around key experiments or trials. The most effective CFOs treat them as designed components of the capital stack, not as occasional windfalls.

Designing the sequence, not just the next round

Moving from opportunistic fundraising to a strategic plan involves a shift in mindset.

1. Define your long range capital map
   Start with the likely number of clinical and regulatory cycles for your core assets. For each phase, estimate order of magnitude costs and potential sources of capital.
2. Set explicit dilution and control thresholds
   Agree with the board the minimum ownership that should be preserved for key stakeholders at critical milestones. Use this to constrain the size and timing of equity raises.
3. Allocate roles for non dilutive funding
   Decide where grants, R&D tax relief and disease foundation funding can materially change the risk profile. For instance, using grants to underwrite early proof of concept, then using tax incentives to support ongoing platform work.
4. Plan for adverse scenarios
   Assume that not all assets will succeed. Model how the capital strategy holds up if one or more programmes are delayed, terminated or require additional work.
5. Embed funding strategy in portfolio decisions
   When prioritising assets, consider not only scientific merit but also the availability of appropriate funding tools. Some indications or modalities may have richer grant or partnership ecosystems than others.

FI Group insight on non dilutive biotech funding

Consultancy FI Group, which advises life sciences and biotech companies on R&D tax relief and grant funding, notes that many organisations still treat non dilutive support as an afterthought once equity rounds are in motion. Their experience is that biotech funding strategies are more resilient when incentives are designed in from the start of each programme.

FI Group’s teams work with CFOs and R&D leaders to map eligible activities across the development portfolio, align evidence collection with laboratory and clinical workflows, and identify grants and innovation programmes in the UK, Europe and the United States that match specific scientific themes. By doing so, they help companies build a recurring layer of non dilutive capital that complements equity, venture debt and partnerships, rather than competing with them. This kind of structured support can be particularly valuable where biotechs are juggling multiple assets and jurisdictions, each with its own incentive rules and timelines.

Common pitfalls in late stage biotech funding

Even experienced teams fall into recognisable traps as programmes progress beyond Series A.

• Serial short termism
  Planning only to the next round can lead to misaligned milestones and rushed deals when markets cool or data arrive later than expected.
• Underestimating working capital needs
  As trials scale, site payments, CRO invoices and manufacturing costs can create liquidity crunches even when headline financing seems adequate.
• Neglecting non dilutive options
  Failing to pursue relevant grants or optimise R&D tax relief can leave material value on the table, especially during pre revenue periods.
• Deal structures that limit future flexibility
  Partnerships that impose broad options or rights of first negotiation can complicate later fundraises or exits if not carefully negotiated.
• Weak integration between scientific and financial planning
  If R&D and finance plan in isolation, trial designs, timelines and capital availability can drift out of sync.

Recognising these patterns early gives CFOs scope to adjust course before constraints become binding.

FAQs on biotech funding beyond Series A

How far ahead should biotech CFOs plan their capital strategy?

While detailed forecasts will always be uncertain, it is sensible to map capital needs across at least two to three major clinical and regulatory cycles, and to review this map regularly as data and external conditions evolve.

What role does non dilutive funding really play in later stages?

Non dilutive tools such as R&D tax relief and grant funding remain relevant beyond early research. They can support platform work, exploratory studies, health economics projects and collaborations that underpin later commercial success, reducing the pressure on pure equity.

When is venture debt appropriate in biotech?

Venture debt is typically most appropriate once there is clear visibility over the next major milestone and a realistic path to follow on funding or partnership revenues. It should not be used to defer difficult strategic decisions or to fund highly speculative programmes.

How should CFOs think about big pharma partnerships in the capital stack?

Partnerships are both validation and funding. CFOs should focus on the balance between upfront payments, milestones and royalties, and on how deal terms interact with future raises, potential acquirers and public incentives. The cheapest capital may not always come from the deal with the highest nominal value.

Can a single funding model work for both platform and asset centric biotechs?

Not usually. Platform companies and asset centric companies have very different risk and return profiles. Platform businesses often rely more on long term equity and broad non dilutive support for infrastructure, while asset centric models lean more on asset specific partnerships and milestone driven capital. A tailored strategy is essential.